1550PRISK OF GASTROINTESTINAL TOXICITIES IN PATIENTS WITH SOLID TUMORS TREATED WITH LAPATINIB; A META ANALYSIS

abdominal pain were 3.44 (95% CI 2.55-4.64; p < 0.00001), 1.27 (95% CI 1.08- 1.49; p < 0.004), 1.29 (95% CI 1.11- 1.51; p =0.001), 1.45 (95% CI 0.98-2.16 p < 0.003), 0.90 [0.57, 1.41] (95% CI 0.57-1.41; p = 0.65); respectively. Exploratory subgroup analysis showed no effect of treatment regimen on the RR of the relevant adverse events. Conclusions: Our meta-analysis has demonstrated that lapatinib is associated with a significantly increased risk of all-grade diarrhea, nausea and vomiting. Clinicians should be aware of these risks and perform regular clinical monitoring. Disclosure: All authors have declared no conflicts of interest.